Characterization of 64Cu-DOTA-conatumumab: A PET tracer for in vivo imaging of death receptor 5

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 942-949

  Rossin, Raffaella ^a   Kohno, Tadahiko ^b   Hagooly, Aviv ^a   Sharp, Terry ^a   Gliniak, Brian ^b   Arroll, Thomas ^c   Chen, Qing ^b   Hewig, Art ^c   Kaplan Lefko, Paula ^b   Friberg, Greg ^b   Radinsky, Robert ^b   Evelhoch, Jeffrey L ^b   Welch, Michael J ^a   Hwang, Dah Ren ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

^c AMGEN INC   (United States)

Author keywords

64Cu; Conatumumab; Death receptor 5; PET; Tracer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CONATUMUMAB; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID CONATUMUMAB CU 64; CASPASE 3; CONATUMUMAB; DEATH RECEPTOR 5; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 64CU DOTA CONATUMUMAB; 64CU-DOTA-CONATUMUMAB; CASPASE 7; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; ANIMAL; AUTORADIOGRAPHY; DOSE RESPONSE; HALF LIFE TIME; ISOTOPE LABELING; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOUSE MUTANT; NEOPLASM; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTORADIOGRAPHY; CASPASE 3; CASPASE 7; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; ISOTOPE LABELING; MICE; MICE, SCID; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION;

EID: 79958093388     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086157     Document Type: Article

References (17)

1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308. (Pubitemid 28406815)
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430. (Pubitemid 37328939)
3. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004;52:821-831. (Pubitemid 38703137)
4. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005;280:2205-2212.
5. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008;118:1979-1990. (Pubitemid 351872316)
6. Kaplan-Lefko PJ, Graves JD, Zoog SJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010;9:618-631.
7. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a proapoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors [abstract]. J Clin Oncol. 2007;25(June 20 suppl):3534.
8. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res. 2010;16:1701-1708.
9. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther. 2006;5:2991-3000. (Pubitemid 46092040)
10. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
11. Tang L. Radionuclide production and yields at Washington University School of Medicine. Q J Nucl Med Mol Imaging. 2008;52:121-133. (Pubitemid 351721931)
12. 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008;8:16.
13. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31:229-234. (Pubitemid 16104025)
14. Sun X, Rossin R, Turner JL, et al. An assessment of the effects of shell crosslinked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules. 2005;6:2541-2554. (Pubitemid 41388265)
15. DeNardo GL, O'Donnell RT, Kroger LA, et al. Strategies for developing effective radioimmunotherapy for solid tumors. Clin Cancer Res. 1999;5:3219s-3223s.
16. Apelgot S, Coppey J, Gaudemer A, et al. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol. 1989;55:365-384. (Pubitemid 19075662)
17. 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res. 2005;11:5112-5120.